Close Menu

NEW YORK – Mobidiag said on Monday that it has received the CE mark for its Amplidiag Resp-4 molecular diagnostic test for the detection of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus.

The assay rapidly and simultaneously detects the viruses, which can cause similar symptoms, from one patient sample using nasopharyngeal swabs. It runs on the Mobidiag Amplidiag Easy PCR platform, which can process up to 46 samples in about three hours, Espoo, Finland-based Mobidiag said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.